Browse Studies — Arctuva | Arctuva

Browse Studies About FAQ

Sign in Get started

Browse studies

Find your next paid study

1 recruiting study matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.

Metastatic Endocrine RefractoryTriple Negative Invasive Lobular Carcinoma

M.D. Anderson Cancer CenterNCT07229417

Arctuva

Connecting verified participants with clinical studies that matter.

Platform

Browse Studies
Join Arctuva
My Profile

Company

About
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Arctuva. All rights reserved.